Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
免疫检查点抑制剂治疗首发癌症与第二原发癌症发生率降低相关。
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2020.100044
Heudel, P; Chabaud, S; Perol, D; Flechon, A; Fayette, J; Combemale, P; Tredan, O; Desseigne, F; de la Fouchardiere, C; Boyle, H; Perol, M; Bachelot, T; Cassier, P; Avrillon, V; Terret, C; Michallet, A-S; Neidhardt-Berard, E-M; Nicolas-Virelizier, E; Dufresne, A; Belhabri, A; Brahmi, M; Lebras, L; Nicolini, F; Sarabi, M; Rey, P; Bonneville-Levard, A; Rochefort, P; Provensal, A-M; Eberst, L; Assaad, S; Swalduz, A; Saintigny, P; Toussaint, P; Guillermin, Y; Castets, M; Coutzac, C; Meeus, P; Dupré, A; Durand, T; Crochet, H; Fervers, B; Gomez, F; Rivoire, M; Gregoire, V; Claude, L; Chassagne-Clement, C; Pilleul, F; Mognetti, T; Russias, B; Soubirou, J-L; Lasset, C; Chvetzoff, G; Mehlen, P; Beaupère, S; Zrounba, P; Ray-Coquard, I; Blay, J-Y